KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Determination of Pharmacokinetic Parameters of Subcutaneous Zyklophin by Quantitative Determination of Zyklophin in Mouse Plasma by LCMS/MS Analysis For Assessment As A Potential Therapeutic Agent In The Treatment of Cocaine Addiction

    Thumbnail
    View/Open
    Mann_ku_0099M_15033_DATA_1.pdf (1.061Mb)
    Issue Date
    2016-12-31
    Author
    Mann, Benjamin
    Publisher
    University of Kansas
    Format
    71 pages
    Type
    Thesis
    Degree Level
    M.S.
    Discipline
    Pharmaceutical Chemistry
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Pharmaceutical agents targeting the μ opioid receptors (MOR) have been widely used in the treatment and management of pain. However, serious side effects and the prevalence of abuse have complicated their administration. This has increased the interest of developing pharmaceutical agents that selectively bind to the κ opioid receptors (KOR). Recent investigation has determined that KOR agonists exhibit a decreased liability for addiction as well as respiratory depression in comparison to MOR agonists. Selectively binding antagonists to the KOR have only been utilized historically as pharmacological tools. Additionally, KOR antagonists show promising potential in therapeutic treatment of depression and anxiety, as well as opiate and cocaine addiction. KOR antagonists that are metabolically stable have been shown to penetrate the CNS. However, peptide-based KOR-selective antagonists are metabolized by proteases and are expected to have a shorter activity than non-peptide KOR-selective antagonists with increased metabolic stability. Through the incorporation of unnatural amino acids as well as conformational constraints in the C terminus, zyklophin experiences increased enzymatic stability. Initial testing has shown that zyklophin crosses the blood brain barrier to antagonize the KOR in the CNS with in vivo administration and that its duration of activity after a system dose is less than 12 hours, whereas a non-peptide KOR antagonist, such as nor-BNI, exhibits duration of activity weeks after a single dose is administered. This prolonged activity complicates its use as a pharmacological tool and as a potential therapeutic agent whereby increasing the importance of peptide-based KOR antagonist. Currently, the FDA has not approved a drug for the prevention of relapse due to cocaine addiction. Peptide-based drugs have been shown to be successful pharmaceutical agents exhibiting high activity, high specificity, low toxicity, and minimal drug-drug interaction. Due to modifications of the C-terminus, zyklophin has an increased metabolic stability. Thus, zyklophin is a good lead compound for the treatment of cocaine addiction and relapse.
    URI
    http://hdl.handle.net/1808/26156
    Collections
    • Pharmaceutical Chemistry Dissertations and Theses [141]
    • Theses [3825]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps